Page last updated: 2024-10-24

keratinocyte proliferation

Definition

Target type: biologicalprocess

The multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population. Keratinocytes are epidermal cells which synthesize keratin and undergo a characteristic change as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. [CL:0000311]

Keratinocyte proliferation is a fundamental process in maintaining the integrity of the epidermis, the outermost layer of skin. It involves a tightly regulated series of events that ensure the continuous renewal of skin cells. The process begins with basal keratinocytes, located in the stratum basale, the deepest layer of the epidermis. These cells are mitotically active and continuously divide to generate new keratinocytes. As new cells are produced, they migrate upwards through the epidermal layers, undergoing a process known as differentiation. This differentiation involves the expression of specific proteins, such as keratins, which contribute to the structural integrity and barrier function of the skin. During their upward migration, keratinocytes undergo a series of changes, including:

* **Increased expression of keratin proteins:** Keratins are fibrous proteins that provide structural support to the skin. As keratinocytes differentiate, they express increasing amounts of keratins, forming the characteristic cytoskeletal framework of the epidermis.
* **Formation of desmosomes:** These specialized cell junctions help to bind keratinocytes together, providing mechanical strength and stability to the skin.
* **Accumulation of lipids:** Keratinocytes synthesize and accumulate lipids, primarily ceramides, which form the skin's barrier function, protecting the body from external insults like water loss and pathogens.
* **Nucleus degradation:** As keratinocytes reach the outermost layer of the epidermis, the stratum corneum, their nuclei degrade, and the cells become flattened and tightly packed, forming the protective barrier layer of the skin.

The entire process of keratinocyte proliferation and differentiation is controlled by a complex interplay of signaling pathways, growth factors, and transcription factors. Some key factors involved in this process include:

* **Epidermal growth factor (EGF):** EGF is a potent mitogen that stimulates keratinocyte proliferation.
* **Transforming growth factor-alpha (TGF-α):** Like EGF, TGF-α promotes keratinocyte proliferation and differentiation.
* **Fibroblast growth factor (FGF):** FGFs are a family of growth factors that play diverse roles in skin development and wound healing, including regulating keratinocyte proliferation and differentiation.
* **Wnt signaling pathway:** This pathway is involved in the regulation of cell fate, proliferation, and differentiation, playing a crucial role in maintaining the balance of keratinocyte populations in the epidermis.
* **Sonic hedgehog (Shh) signaling pathway:** Shh signaling regulates epidermal stem cell proliferation and differentiation.

Proper keratinocyte proliferation and differentiation are essential for skin health. Dysregulation of this process can lead to various skin disorders, including psoriasis, eczema, and skin cancer. Understanding the mechanisms underlying keratinocyte proliferation is crucial for developing effective therapies for these conditions.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Peroxisome proliferator-activated receptor deltaA peroxisome proliferator-activated receptor delta that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q03181]Homo sapiens (human)
Kallikrein-8A kallikrein-8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60259]Homo sapiens (human)

Compounds (46)

CompoundDefinitionClassesRoles
gw 2433GW 2433: binds peroxisome proliferator-activated receptor alpha (PPARalpha); structure in first source
clofibric acidclofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.

Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
aromatic ether;
monocarboxylic acid;
monochlorobenzenes
anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
pirinixic acidpirinixic acid: structurearyl sulfide;
organochlorine compound;
pyrimidines
methyleugenolmethyleugenol: structurephenylpropanoid
myristic acidMyristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed)

tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.

tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.
long-chain fatty acid;
straight-chain saturated fatty acid
algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite
bezafibratearomatic ether;
monocarboxylic acid;
monocarboxylic acid amide;
monochlorobenzenes
antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenofibric acidfenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.

fenofibric acid: RN given refers to parent cpd without isomeric designation; structure
aromatic ketone;
chlorobenzophenone;
monocarboxylic acid
drug metabolite;
marine xenobiotic metabolite
telmisartantelmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.

Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.
benzimidazoles;
biphenyls;
carboxybiphenyl
angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
rosiglitazoneaminopyridine;
thiazolidinediones
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
2-bromopalmitate2-bromohexadecanoic acid : A bromo fatty acid that is hexadecanoic (palmitic) acid carrying a single bromo substituent at position 2.

2-bromopalmitate: inhibitor of fatty acid oxidation; RN given refers to parent cpd
2-bromocarboxylic acid;
bromo fatty acid;
long-chain fatty acid;
straight-chain fatty acid
fatty acid oxidation inhibitor
mk 7675-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source
anacardic acidanacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.

anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor
hydroxy monocarboxylic acid;
hydroxybenzoic acid
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite
farglitazarfarglitazar: a non-thiazolidinedione insulin sensitiser and PPARgamma agonist
syringaresinol(+)-syringaresinol : The (7alpha,7'alpha,8alpha,8'alpha)-stereoisomer of syringaresinol.syringaresinolantineoplastic agent
oleic acidoleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.

Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)
octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
epipinoresinolepipinoresinol : An enantiomer of pinoresinol having (+)-(1R,3aR,4S,6aR)-configuration.pinoresinolmarine metabolite;
plant metabolite
t 0070907T 0070907: a PPARgamma antagonist; structure in first sourcecarbonyl compound;
organohalogen compound
gsk 3787
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source
gw 7647GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.

GW 7647: a PPAR-alpha agonist; structure in first source
aryl sulfide;
monocarboxylic acid;
ureas
PPARalpha agonist
psi-baptigeninpseudobaptigenin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone and in which the phenyl group at position 3 is replaced by a 1,3-benzodioxol-5-yl group.7-hydroxyisoflavones;
benzodioxoles
antiprotozoal drug;
plant metabolite
n-oleoylethanolamineN-oleoylethanolamine: ceramidase inhibitor

oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.
endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1
EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
pregna-4,17-diene-3,16-dionepregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor3-hydroxy steroidandrogen
gw 1929GW 1929: activates peroxisome proliferator-activated receptor-gamma; structure in first sourcebenzophenones
l-1650414-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.aromatic ketone
gw 501516GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.

GW 501516: a selective PPARdelta agonist; structure in first source
1,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound
carcinogenic agent;
PPARbeta/delta agonist
tzd 18
gft505
gw 9578GW 9578: a peroxisome proliferator-activated receptor alpha agonist; structure in first source
gw 7845GW 7845: ligand of the peroxisome proliferator-activated receptor-gamma; structure in first source
naveglitazarnaveglitazar: LY-519818 is the (alpha-S)-isomer; an antidiabetic agent; structure in first sourcearomatic ether
l 796449L 796449: a peroxisomal proliferator-activated receptor-gamma agonist; structure in first source
gw0742GW 610742: structure in first sourcemonocarboxylic acid
3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid
ns-220
gw 5907352-methyl-2-(4-(((4-methyl-2-(4-trifluoromethylphenyl)-thiazol-5-ylcarbonyl)amino)methyl)phenoxy)propionic acid: an HDLc raising agent; structure in first source
aleglitazaraleglitazar: a dual peroxisome PPAR-alpha and PPAR-gamma agonist for type 2 diabetes
mbx-8025seladelpar: PPAR-delta agonist
gw9508GW9508: structure in first sourcearomatic amine
lj 529
bms 687453
amorfrutin aamorfrutin A: an antidiabetic agent that inhibits NF-kappaB activation; structure in first sourcestilbenoid
amorfrutin bamorfrutin B: structure in first source
grassystatin agrassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source
gsk0660GSK0660: PPAR antagonist; structure in first sourcesulfonamide
ly 518674LY 518674: a peroxisome proliferator-activated receptor alpha agonist; structure in first source